ライフサイエンスコーパス: dyscrasia

1 n to multiple myeloma or another plasma cell dyscrasia.

2 ing patients with oligosecretory plasma cell dyscrasia.

3 fter relapse of their underlying plasma cell dyscrasia.

4 der resulting from an underlying plasma cell dyscrasia.

5 ng eradication of the underlying plasma cell dyscrasia.

6 a rare disease associated with a plasma cell dyscrasia.

7 nontreatment-related factors in plasma cell dyscrasias.

8 bule epithelium, particularly in plasma cell dyscrasias.

9 at are seen in patients who have plasma cell dyscrasias.

10 into the molecular mechanisms of plasma-cell dyscrasias.

11 ence of an opportunistic infection and blood dyscrasias.

12 standing normal hematopoiesis and blood cell dyscrasias.

13 ying genetic determinants of inherited blood dyscrasias.

14 ent is a frequent consequence of plasma cell dyscrasias.

15 as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of

16 nce of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mechanism of monoclonal gammopa

17 ight chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage vital organs.

18 lts also help elucidate the link between RBC dyscrasias and cardiovascular morbidity.

19 implicated in the pathogenesis of autoimmune dyscrasias and malignant diseases.

20 healthy individuals at risk for plasma cell dyscrasias and that dominant inheritance of posttranslat

21 tution following rituximab leading to immune dyscrasias and the development of neutropenia.

22 Plasma cell dyscrasias appear to have a modestly increased incidence

23 s of gene methylated for L/L and plasma cell dyscrasias are different.

24 Plasma cell dyscrasias are frequently encountered malignancies often

25 Plasma cell dyscrasias are frequently encountered malignancies which

26 Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production of immunogl

27 Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of multiple myel

28 patients with heavily pretreated plasma cell dyscrasias completing one cycle of therapy, there was on

29 %) at 12 months after treatment, plasma cell dyscrasias could not be detected.

30 r factor-kappaB may play a role in the blood dyscrasias encountered with the use of this drug.

31 sed for the initiation of drug-induced blood dyscrasias, hypersensitivity reactions, or lupus-like sy

32 ieve complete remission of their plasma cell dyscrasia, improvement in performance status, and clinic

33 ntation induces remission of the plasma cell dyscrasia in a substantial proportion of patients with A

34 sive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the amelioration

35 associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal immunoglobuli

36 Plasma cell dyscrasias, including monoclonal gammopathy of undetermi

37 determined significance or other plasma cell dyscrasias involving the bone marrow, express the Wnt-si

38 d not the result of a monoclonal plasma cell dyscrasia, may be misdiagnosed and lead to inappropriate

39 ases in malignancies such as the plasma cell dyscrasia multiple myeloma (MM) is not known.

40 differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multisystem illne

41 POEMS syndrome is a rare plasma cell dyscrasia presenting with polyneuropathy and other syste

42 pathophysiology and diagnosis of plasma cell dyscrasia related kidney diseases.

43 to expand, but the cause of this plasma cell dyscrasia remains unclear.

44 y systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death.

45 In the setting of a plasma cell dyscrasia, significant amounts of free light chains, now

46 largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined

47 the molecular defects underlying plasma cell dyscrasias that may explain their clinical heterogeneity

48 arcinoma, malignant melanoma, or plasma cell dyscrasia, we related responses to questionnaires (admin

49 Their plasma cell dyscrasias were evaluated with immunofixation electropho

50 ious liver toxic effects or white-blood-cell dyscrasias were noted.

51 Well-selected patients with plasma cell dyscrasias whose monoclonal Ig is well controlled may be

52 temic amyloidosis (AL) is a plasma cell (PC) dyscrasia with clinical similarities to multiple myeloma

53 e myeloma (SMM) are asymptomatic plasma cell dyscrasias, with a propensity to progress to symptomatic

54 ies had two or more members with plasma cell dyscrasias, with or without a single case of MM.